-
Something wrong with this record ?
Hyperfractionated stereotactic reirradiation for recurrent head and neck cancer
J. Cvek, L. Knybel, E. Skacelikova, J. Stransky, P. Matousek, K. Zelenik, O. Res, B. Otahal, L. Molenda, D. Feltl,
Language English Country Germany
Document type Comparative Study, Journal Article, Research Support, Non-U.S. Gov't
NLK
ProQuest Central
from 1997-01-01 to 2017-12-31
Medline Complete (EBSCOhost)
from 2006-08-01 to 1 year ago
Nursing & Allied Health Database (ProQuest)
from 1997-01-01 to 2017-12-31
Health & Medicine (ProQuest)
from 1997-01-01 to 2017-12-31
Public Health Database (ProQuest)
from 1997-01-01 to 2017-12-31
- MeSH
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Neoplasm Recurrence, Local pathology surgery MeSH
- Survival Rate MeSH
- Retreatment MeSH
- Otorhinolaryngologic Neoplasms pathology surgery MeSH
- Postoperative Complications etiology MeSH
- Disease Progression MeSH
- Radiosurgery methods MeSH
- Neoplasms, Second Primary pathology surgery MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Carcinoma, Squamous Cell pathology surgery MeSH
- Neoplasm Staging MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Comparative Study MeSH
PURPOSE: The goal of this work was to evaluate the efficacy and toxicity of hyperfractionated stereotactic reirradiation (re-RT) as a treatment for inoperable, recurrent, or second primary head and neck squamous cell cancer (HNSCC) that is not suitable for systemic treatment. PATIENTS AND MATERIALS: Forty patients with recurrent or second primary HNSCC were included in this study. The patients had a median gross tumor volume of 76 ml (range 14-193 ml) and a previous radiotherapy dose greater than 60 Gy. Treatment was designed to cover 95 % of the planning target volume (PTV, defined as gross tumor volume [GTV] + 3 mm to account for microscopic spreading, with no additional set-up margin) with the prescribed dose (48 Gy in 16 fractions b.i.d.). Treatment was administered twice daily with a minimum 6 h gap. Uninvolved lymph nodes were not irradiated. RESULTS: Treatment was completed as planned for all patients (with median duration of 11 days, range 9-14 days). Acute toxicity was evaluated using the RTOG/EORTC scale. A 37 % incidence of grade 3 mucositis was observed, with recovery time of ≤ 4 weeks for all of these patients. Acute skin toxicity was never observed to be higher than grade 2. Late toxicity was also evaluated according to the RTOG/EORTC scale. Mandible radionecrosis was seen in 4 cases (10 %); however, neither carotid blowout syndrome nor other grade 4 late toxicity occurred. One-year overall survival (OS) and local progression-free survival (L-PFS) were found to be 33 and 44 %, respectively. Performance status and GTV proved to be significant prognostic factors regarding local control and survival. CONCLUSION: Hyperfractionated stereotactic re-RT is a reasonable treatment option for patients with recurrent/second primary HNSCC who were previously exposed to high-dose irradiation and who are not candidates for systemic treatment or hypofractionation.
Department of Maxilofacial Surgery University Hospital Ostrava Ostrava Czech Republic
Department of Oncology University Hospital Ostrava listopadu 1790 708 52 Ostrava Czech Republic
Department of Otolaryngology University Hospital Ostrava Ostrava Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16020349
- 003
- CZ-PrNML
- 005
- 20160809110536.0
- 007
- ta
- 008
- 160722s2016 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00066-015-0886-3 $2 doi
- 024 7_
- $a 10.1007/s00066-015-0886-3 $2 doi
- 035 __
- $a (PubMed)26314584
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Cvek, Jakub $u Department of Oncology, University Hospital Ostrava, listopadu 1790, 708 52, Ostrava, Czech Republic. jakub.cvek@fno.cz.
- 245 10
- $a Hyperfractionated stereotactic reirradiation for recurrent head and neck cancer / $c J. Cvek, L. Knybel, E. Skacelikova, J. Stransky, P. Matousek, K. Zelenik, O. Res, B. Otahal, L. Molenda, D. Feltl,
- 520 9_
- $a PURPOSE: The goal of this work was to evaluate the efficacy and toxicity of hyperfractionated stereotactic reirradiation (re-RT) as a treatment for inoperable, recurrent, or second primary head and neck squamous cell cancer (HNSCC) that is not suitable for systemic treatment. PATIENTS AND MATERIALS: Forty patients with recurrent or second primary HNSCC were included in this study. The patients had a median gross tumor volume of 76 ml (range 14-193 ml) and a previous radiotherapy dose greater than 60 Gy. Treatment was designed to cover 95 % of the planning target volume (PTV, defined as gross tumor volume [GTV] + 3 mm to account for microscopic spreading, with no additional set-up margin) with the prescribed dose (48 Gy in 16 fractions b.i.d.). Treatment was administered twice daily with a minimum 6 h gap. Uninvolved lymph nodes were not irradiated. RESULTS: Treatment was completed as planned for all patients (with median duration of 11 days, range 9-14 days). Acute toxicity was evaluated using the RTOG/EORTC scale. A 37 % incidence of grade 3 mucositis was observed, with recovery time of ≤ 4 weeks for all of these patients. Acute skin toxicity was never observed to be higher than grade 2. Late toxicity was also evaluated according to the RTOG/EORTC scale. Mandible radionecrosis was seen in 4 cases (10 %); however, neither carotid blowout syndrome nor other grade 4 late toxicity occurred. One-year overall survival (OS) and local progression-free survival (L-PFS) were found to be 33 and 44 %, respectively. Performance status and GTV proved to be significant prognostic factors regarding local control and survival. CONCLUSION: Hyperfractionated stereotactic re-RT is a reasonable treatment option for patients with recurrent/second primary HNSCC who were previously exposed to high-dose irradiation and who are not candidates for systemic treatment or hypofractionation.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a spinocelulární karcinom $x patologie $x chirurgie $7 D002294
- 650 _2
- $a progrese nemoci $7 D018450
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a lokální recidiva nádoru $x patologie $x chirurgie $7 D009364
- 650 _2
- $a staging nádorů $7 D009367
- 650 _2
- $a sekundární malignity $x patologie $x chirurgie $7 D016609
- 650 _2
- $a otorinolaryngologické nádory $x patologie $x chirurgie $7 D010039
- 650 _2
- $a pooperační komplikace $x etiologie $7 D011183
- 650 _2
- $a radiochirurgie $x metody $7 D016634
- 650 _2
- $a opakovaná terapie $7 D019233
- 650 _2
- $a míra přežití $7 D015996
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Knybel, Lukas $u Department of Oncology, University Hospital Ostrava, listopadu 1790, 708 52, Ostrava, Czech Republic.
- 700 1_
- $a Skacelikova, Eva $u Department of Oncology, University Hospital Ostrava, listopadu 1790, 708 52, Ostrava, Czech Republic.
- 700 1_
- $a Stransky, Jiri $u Department of Maxilofacial Surgery, University Hospital Ostrava, Ostrava, Czech Republic.
- 700 1_
- $a Matousek, Petr $u Department of Otolaryngology, University Hospital Ostrava, Ostrava, Czech Republic.
- 700 1_
- $a Zelenik, Karol $u Department of Otolaryngology, University Hospital Ostrava, Ostrava, Czech Republic.
- 700 1_
- $a Res, Oldrich $u Department of Maxilofacial Surgery, University Hospital Ostrava, Ostrava, Czech Republic.
- 700 1_
- $a Otahal, Bretislav $u Department of Oncology, University Hospital Ostrava, listopadu 1790, 708 52, Ostrava, Czech Republic.
- 700 1_
- $a Molenda, Lukas $u Department of Oncology, University Hospital Ostrava, listopadu 1790, 708 52, Ostrava, Czech Republic.
- 700 1_
- $a Feltl, David $u Department of Oncology, University Hospital Ostrava, listopadu 1790, 708 52, Ostrava, Czech Republic.
- 773 0_
- $w MED00010658 $t Strahlentherapie und Onkologie Organ der Deutschen Röntgengesellschaft ... [et al] $x 1439-099X $g Roč. 192, č. 1 (2016), s. 40-6
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26314584 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160722 $b ABA008
- 991 __
- $a 20160809110813 $b ABA008
- 999 __
- $a ok $b bmc $g 1155019 $s 944877
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 192 $c 1 $d 40-6 $e 20150828 $i 1439-099X $m Strahlentherapie und Onkologie $n Strahlenther Onkol $x MED00010658
- LZP __
- $a Pubmed-20160722
